IPF FBs and control HPFs were treated with either R428 (Axl-specific inhibitor), LDC1267 (TAM inhibitor), or Nintedanib at a range of concentrations (from 0.01 to 100 μM) for 48 h. The gene discussed is AXL; the disease is idiopathic pulmonary fibrosis.